Managing Bortezomib-Induced Neuropathy

In this article, we discuss a common and painful side effect associated with cancer treatment.

Recent Content

Of the 39 advanced gastric cancer patients treated with the immunotherapy antibody, pembrolizumab (Keytruda, Merck), 22.2% had an objective response. The median time to response was 8 weeks and the median progression-free survival (PFS) was 1.9 months

The PD-1 inhibitor nivolumab increased progression-free and overall survival compared with chemo in patients with previously untreated metastatic melanoma.

No difference in anxiety was found among patients with non-Hodgkin lymphoma who were assigned to maintenance rituximab compared with those patients who were assigned to rituximab re-treatment upon disease progression, results of a recent study show.

Researchers at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, have discovered a protein that could help treat certain lymphomas, including those resistant to therapy.

For patients with metastatic clear cell renal cell carcinoma (mccRCC), administering a sequential, second-line tyrosine kinase inhibitor (TKI) may be more beneficial over a mammalian target of rapamycin inhibitor (mTORi).

A drug used to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), is also helping to boost the effectiveness of radiation for those melanoma patients with metastasis to the brain.

A mechanism that leads to resistance to certain targeted therapy drugs for melanoma has been discovered by researchers at the Moffitt Cancer Center in Tampa, Fla.

By clicking Accept, you agree to become a member of the UBM Medica Community.